HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma: The HDAC inhibitor-based combination therapy exhibited better efficacy when compared with HDAC inhibitor monotherapy for R/R PTCL patients (<i>P</i> = 0.02).